HH domain of Alzheimer's disease Aβ provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Poduslo, Joseph F ^a   Gilles, Emily J ^a   Ramakrishnan, Muthu ^a   Howell, Kyle G ^a   Wengenack, Thomas M ^a   Curran, Geoffry L ^a   Kandimalla, Karunya K ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; HISTIDINE; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CELL; BRAIN NERVE CELL; BRAIN SLICE; CELL INTERACTION; CONTROLLED STUDY; FIBER; FLOW CYTOMETRY; HIPPOCAMPUS; HUMAN; HUMAN CELL; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PROTEIN BINDING; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEURONS; PC12 CELLS; RATS; SPECTROMETRY, FLUORESCENCE; SURFACE PLASMON RESONANCE;

MUS MUSCULUS;

EID: 77749249568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008813     Document Type: Article

References (46)

1. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32: 177-180.
2. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, et al. (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58: 42-51.
3. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G (1997) Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100: 310-320.
4. Guo Q, Fu W, Xie J, Luo H, Sells SF, et al. (1998) Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 4: 957-962.
5. Wirths O, Multhaup G, Bayer TA (2004) A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J Neurochem 91: 513-520.
6. Echeverria V, Cuello AC (2002) Intracellular A-beta amyloid, a sign for worse things to come? Mol Neurobiol 26: 299-316.
7. Tseng BP, Kitazawa M, LaFerla FM (2004) Amyloid beta-peptide: the inside story. Curr Alzheimer Res 1: 231-239.
8. Gouras GK, Almeida CG, Takahashi RH (2005) Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 26: 1235-1244.
9. Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S (2000) Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 355: 42-43.
10. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, et al. (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15-20.
11. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, et al. (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5: 560-564.
12. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38: 120-134.
13. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF (2009) Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid-beta protein. PloS One 4: e4627.
14. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, et al. (1998) The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 273: 29719-29726.
15. Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, et al. (1999) Competition of Abeta amyloid peptide and apolipoprotein E for receptormediated endocytosis. J Lipid Res 40: 447-455.
16. Diaz JC, Linnehan J, Pollard H, Arispe N (2006) Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease Abeta ion channel and cytotoxicity. Biol Res 39: 447-460.
17. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, et al. (2005) Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 280: 13355-13363.
18. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, et al. (2006) Coppermediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281: 15145-15154.
19. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K (1991) Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol 218: 149-163.
20. Fraser PE, Nguyen JT, Inouye H, Surewicz WK, Selkoe DJ, et al. (1992) Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 31: 10716-10723.
21. Fung J, Frost D, Chakrabartty A, McLaurin J (2004) Interaction of human and mouse Abeta peptides. J Neurochem 91: 1398-1403.
22. Shivers BD, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, et al. (1988) Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. Embo J 7: 1365-1370.
23. Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE (2000) Examining the zinc binding site of the amyloid-beta peptide. Eur J Biochem 267: 6692-6698.
24. Liu ST, Howlett G, Barrow CJ (1999) Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry 38: 9373-9378.
25. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, et al. (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265: 1464-1467.
26. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, et al. (1999) Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111-37116.
27. Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, et al. (2008) Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A 105: 6813-6818.
28. Collingridge GL (1995) The brain slice preparation: a tribute to the pioneer Henry McIlwain. J Neurosci Methods 59: 5-9.
29. Xu H, Sweeney D, Greengard P, Gandy S (1996) Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proc Natl Acad Sci U S A 93: 4081-4084.
30. Fukuda M, Yamamoto A (2004) Effect of forskolin on synaptotagmin IV protein trafficking in PC12 cells. J Biochem 136: 245-253.
31. Gredell JA, Turnquist PA, Maciver MB, Pearce RA (2004) Determination of diffusion and partition coefficients of propofol in rat brain tissue: implications for studies of drug action in vitro. Br J Anaesth 93: 810-817.
32. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, et al. (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151: 229-238.
33. Wengenack TM, Curran GL, Poduslo JF (2000) Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18: 868-872.
34. Mukherjee S, Ghosh RN, Maxfield FR (1997) Endocytosis. Physiol Rev 77: 759-803.
35. Miya K, Inoue R, Takata Y, Abe M, Natsume R, et al. (2008) Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510: 641-654.
36. Morris AM, Watzky MA, Agar JN, Finke RG (2008) Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry 47: 2413-2427.
37. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, et al. (2004) Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 43: 6064-6075.
38. Simakova O, Arispe NJ (2007) The cell-selective neurotoxicity of the Alzheimer's Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J Neurosci 27: 13719-13729.
39. Bi X, Gall CM, Zhou J, Lynch G (2002) Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112: 827-840.
40. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110: 199-211.
41. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-[beta] in Alzheimer's disease. 8: 499-509.
42. Lee G, Pollard HB, Arispe N (2002) Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23: 1249-1263.
43. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, et al. (2008) Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci 28: 11950-11958.
44. Ciccotosto GD, Tew DJ, Drew SC, Smith DG, Johanssen T, et al. (2009) Stereospecific interactions are necessary for Alzheimer disease amyloid-beta toxicity. Neurobiol Aging: In Press.
45. Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P (2003) The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 302: 822-826.
46. Guntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloidbeta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143: 461-475.